文献速递眼底病与葡萄膜炎

一线抗代谢药作为激素节省治疗葡萄膜炎试验中葡萄膜炎性黄斑水肿的结局

Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.
PubMed 文献 · Ophthalmology · 2022-02-08

FAST试验亚组分析,比较甲氨蝶呤与吗替麦考酚酯治疗葡萄膜炎性黄斑水肿的6个月和12个月结局。两组黄斑厚度改善相似(12个月P=0.73和P=0.34),黄斑水肿消退率无显著差异(P=0.10和P=0.92)。12个月时每组约半数眼仍存在持续性黄斑水肿。

要点

  • 甲氨蝶呤与吗替麦考酚酯治疗葡萄膜炎性黄斑水肿,12个月黄斑厚度改善相似。
  • 12个月时甲氨蝶呤组37%眼黄斑水肿消退,吗替麦考酚酯组60%,差异无统计学意义(P=0.10)。
  • 12个月时每组约半数眼仍存在持续性黄斑水肿。

核心结论

  • 甲氨蝶呤或吗替麦考酚酯治疗葡萄膜炎性黄斑水肿在6个月和12个月时黄斑厚度改善相似。
  • 12个月时每种抗代谢药组约半数眼仍存在持续性黄斑水肿。

研究设计与样本

  • FAST试验的亚组分析,采用区组随机、观察者设盲、多中心临床试验设计。
  • 2013年8月至2017年8月入组,患者随机接受口服甲氨蝶呤25 mg每周一次或吗替麦考酚酯1.5 g每日两次治疗12个月,并联合糖皮质激素逐渐减量。
  • 216例患者中,甲氨蝶呤组42眼(30例患者)和吗替麦考酚酯组55眼(41例患者)存在葡萄膜炎性黄斑水肿。
  • 6个月主要终点时治疗成功者继续原治疗6个月,治疗失败者换用另一治疗组。

主要发现

  • 基线中位中央子区域厚度在甲氨蝶呤组和吗替麦考酚酯组分别为359 μm和342 μm。
  • 12个月时,继续原治疗者黄斑厚度较基线分别下降30.5 μm(四分位距[IQR],-132.3至4.0)和54 μm(IQR,-95.5至-4.5)(P=0.73)。
  • 6个月时换药者黄斑厚度较基线分别下降12.5 μm(IQR,-32.3至-0.5)和50 μm(IQR,-181.0至-10.0)(P=0.34)。
  • 12个月时,甲氨蝶呤组19眼中7眼(37%)黄斑水肿消退,吗替麦考酚酯组25眼中15眼(60%)消退(P=0.10)。
  • 换药者中,甲氨蝶呤组17眼中8眼(47%)和吗替麦考酚酯组11眼中6眼(55%)黄斑水肿消退(P=0.92)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the outcomes of uveitic macular edema at 6 and 12 months in patients treated with methotrexate or mycophenolate mofetil. DESIGN: Subanalysis of a block-randomized, observer-masked, multicenter clinical trial. PARTICIPANTS: Patients were enrolled in the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial between August 2013 and August 2017. METHODS: Patients were randomized to oral methotrexate 25 mg weekly or mycophenolate mofetil 1.5 g twice daily for 12 months, along with a corticosteroid taper. In addition to standardized clinical examination, all patients underwent spectral-domain OCT imaging at each visit. At the 6-month primary end point, patients who achieved treatment success continued the same treatment for a subsequent 6 months, and treatment failures switched to the other treatment group. MAIN OUTCOME MEASURES: Prespecified 6-month primary outcome and 12-month outcomes of central subfield thickness and visual acuity. RESULTS: Of 216 patients in the FAST Trial, 42 eyes (30 patients) in the methotrexate group and 55 eyes (41 patients) in the mycophenolate group had uveitic macular edema. Baseline median central subfield thickness was 359 μm and 342 μm in the methotrexate and mycophenolate groups, respectively. At 12 months, for those who stayed on the same treatment, macular thickness decreased from baseline by 30.5 μm (interquartile range [IQR], -132.3 to 4.0) and 54 μm (IQR, -95.5 to -4.5) in the methotrexate and mycophenolate groups, respectively (P = 0.73). In patients who switched treatment at 6 months, macular thickness decreased from baseline by 12.5 μm (IQR, -32.3 to -0.5) and 50 μm (IQR, -181.0 to -10.0) in the methotrexate and mycophenolate groups, respectively (P = 0.34). At 12 months, 7 of 19 eyes (37%) on methotrexate had resolution of macular edema compared with 15 of 25 eyes (60%) on mycophenolate (P = 0.10). For those who switched treatments, 8 of 17 eyes (47%) on methotrexate and 6 of 11 eyes (55%) on mycophenolate had resolution of macular edema (P = 0.92). CONCLUSIONS: Treatment with methotrexate or mycophenolate mofetil for uveitic macular edema results in similar improvements in macular thickness at 6 and 12 months. At 12 months, approximately half of eyes in each antimetabolite group still had persistent macular edema.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Tsui E, Rathinam SR, Gonzales JA, et al. Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial. Ophthalmology. 2022. PMID: 35143800. doi:10.1016/j.ophtha.2022.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。